Patients
3.1 % of people
People aged 65 and over, Saudi Arabia, 2025 (World Bank).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Saudi Arabia Sarcopenia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$66.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $57.6 Mn | — | — |
| 2025 (base) | $62.4 Mn | +$4.8 Mn | — |
| 2026 (forecast) | $67.6 Mn | +$5.2 Mn | +8.4% |
| 2027 (forecast) | $73.3 Mn | +$5.7 Mn | +17.5% |
| 2028 (forecast) | $79.5 Mn | +$6.2 Mn | +27.4% |
| 2029 (forecast) | $86.2 Mn | +$6.7 Mn | +38.1% |
| 2030 (forecast) | $93.4 Mn | +$7.2 Mn | +49.7% |
| 2031 (forecast) | $101.2 Mn | +$7.8 Mn | +62.2% |
| 2032 (forecast) | $109.7 Mn | +$8.5 Mn | +75.9% |
| 2033 (forecast) | $119.0 Mn | +$9.2 Mn | +90.6% |
| 2034 (forecast) | $128.9 Mn | +$10.0 Mn | +106.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $62.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $128.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, product and end user (see all) |
| Key players | Abbott Laboratories, Nestle, Regeneron Pharmaceuticals, Scholar Rock, Biophytis (see all) |
| Regulator in Saudi Arabia | SFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Sarcopenia treatment aims to slow or reverse age-related loss of muscle mass and strength with nutrition, exercise and new medicines.
Key segments of the sarcopenia Treatment market include treatment (Nutritional Supplements, Exercise Programs and Pharmacological Therapy) and product (Protein and Amino Acids, Vitamin D and Myostatin Inhibitors).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the sarcopenia Treatment market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the sarcopenia Treatment market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the sarcopenia Treatment market.
The sarcopenia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The Saudi Food and Drug Authority (SFDA) registers medicines before sale.[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).[2] People aged 65 and over: 3.1% of people in 2025, the latest World Bank figure for Saudi Arabia.[3]
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Council of Health Insurance. Checked 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sarcopenia Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.
What doctors and scientists are doing in Sarcopenia Treatment right now, from free public sources.
3.1 % of people
People aged 65 and over, Saudi Arabia, 2025 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 16 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
From our blog
Saudi Arabia · 1 shared keyword
Saudi Arabia
Saudi Arabia
Saudi Arabia
Saudi Arabia
Saudi Arabia
OTC & Nutraceuticals · Saudi Arabia
Healthcare Services · Saudi Arabia
Digital Health · Saudi Arabia
OTC & Nutraceuticals · Saudi Arabia
OTC & Nutraceuticals · Saudi Arabia
OTC & Nutraceuticals · Saudi Arabia